Fibrosis in Autoimmune and Cholestatic Liver Disease
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Autoimmune and cholestatic liver disease account for a significant part of end-stage liver disease and are leading indications for liver transplantation. Especially cholestatic liver diseases (primary biliary cirrhosis and primary sclerosing cholangitis) appear to be different from other chronic liver diseases with regards to pathogenesis. Portal fibroblasts located in the connective tissue surrounding bile ducts appear to be different from hepatic stellate cells with regards to expression of marker proteins and response the profibrogenic and mitogenic stimuli. In addition there is increasing evidence for a cross talk between activated cholangiocytes and portal myofibroblasts. Several animal models have improved our understanding of the mechanisms underlying these chronic liver diseases. In the present review, we discuss the current concepts and ideas with regards to myofibroblastic cell populations, mechanisms of fibrosis, summarize characteristic histological findings and currently employed animal models of autoimmune and cholestatic liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Kulkarni, A. B., Huh, C. G., Becker, D., Geiser, A., Lyght, M., Flanders, K. C., Roberts, A. B., Sporn, M. B., Ward, J. M., & Karlsson, S. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.770 · Cited by 1,967 · cited 1×
“Accordingly, mice lacking TGFβ1 display excessive inflammation characterized by inflammatory lesions primarily in the heart and lungs resembling autoimmune disorders [69].”
BackgroundDiagnosis and management of autoimmune hepatitis
Manns, M. P., Czaja, A. J., Gorham, J. D., Krawitt, E. L., Mieli-Vergani, G., Vergani, D., & Vierling, J. M. (2010) · Hepatology · doi:10.1002/hep.23584 · Cited by 1,442
Kaplan, M. M., & Gershwin, M. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043898 · Cited by 1,144
Hepatic lipocytes: the principal collagen-producing cells of normal rat liver.
Friedman, S. L., Roll, F. J., Boyles, J., & Bissell, D. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.24.8681 · Cited by 859
Chazouillères, O., Wendum, D., Serfaty, L., Montembault, S., Rosmorduc, O., & Poupon, R. (1998) · Hepatology · doi:10.1002/hep.510280203 · Cited by 746 · cited 1×
“Importantly, histological features canoverlapwith those of PSC or PBC and a careful histological examination is therefore mandatory [67,68].”
BackgroundGershwin, M. E., Mackay, I. R., Sturgess, A., & Coppel, R. L. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.10.3525 · Cited by 557
Hepatic stellate cell lipid droplets: A specialized lipid droplet for retinoid storage
Blaner, W. S., O'Byrne, S. M., Wongsiriroj, N., Kluwe, J., D'Ambrosio, D. M., Jiang, H., Schwabe, R. F., Hillman, E. M. C., Piantedosi, R., & Libien, J. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2008.11.001 · Cited by 444 · cited 1×
“Proteins involved in vitamin A metabolism, including cellular retinol-binding proteins (CRBP) or lecithin-retinol acyltransferase (LRAT) are therefore potential markers for specific identification of HSC [5,8,9].”
BackgroundRoll, J., Boyer, J. L., Barry, D., & Klatskin, G. (1983) · New England Journal of Medicine · doi:10.1056/nejm198301063080101 · Cited by 417 · cited 1×
“5 years [44,46,47].”
The natural history of small-duct primary sclerosing cholangitis
Björnsson, E., Olsson, R., Bergquist, A., Lindgren, S., Braden, B., Chapman, R. W., Boberg, K. M., & Angulo, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.042 · Cited by 305 · cited 1×
“Notably 20% of patients develop regular, large duct PSC [78].”
Background
Cited by
Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
Parola, M., & Pinzani, M. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.09.002 · Cited by 1,160
Cellular Mechanisms of Liver Fibrosis
Acharya, P., Chouhan, K., Weiskirchen, S., & Weiskirchen, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.671640 · Cited by 252
Baghdasaryan, A., Fuchs, C. D., Österreicher, C. H., Lemberger, U. J., Halilbasic, E., Påhlman, I., Graffner, H., Krones, E., Fickert, P., Wahlström, A., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.024 · Cited by 187
Self-citationSpatial transcriptomics identifies enriched gene expression and cell types in human liver fibrosis
Chung, B. K., Øgaard, J., Reims, H. M., Karlsen, T. H., & Melum, E. (2022) · Hepatology Communications · doi:10.1002/hep4.2001 · Cited by 85
“[1] Development of cirrhosis is a gradual process, and fibrosis severity is known to correlate with adverse patient outcomes.[2,3] At present, no clinical approved antifibrotic treatments for liver fibrosis are available except for liver transplantation,[4] and despite major advances in the recent years, the key pathw…”
BackgroundBrovold, M., Keller, D., Devarasetty, M., Dominijanni, A., Shirwaiker, R., & Soker, S. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10207 · Cited by 11
“tain normal bile flow through the entire biliary tract resulting in cholestasis.(1) Major lifelong comorbidities include portal hypertension, cirrhosis, and an increased likelihood of hepatocarcinoma and cholangiocarcinoma.”
Background
Metadata
- Authors
- Penz-Österreicher, M., Österreicher, C. H., & Trauner, M.
- Venue
- Best Practice & Research Clinical Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2011-04
- Volume
- 25
- Issue
- 2
- Pages
- 245-258
- ISSN
- 1521-6918 (ISSN-L)
- OpenAlex
- W2057855837
- Cited by
- 84
- References
- 19
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.